Skip to content

Commit

Permalink
Commit from GitHub Actions (Update Indications on Merge)
Browse files Browse the repository at this point in the history
  • Loading branch information
@TanskaAnnna
TanskaAnnna committed Jul 14, 2021
1 parent 95514c4 commit 2c6f658
Show file tree
Hide file tree
Showing 3 changed files with 116 additions and 1,491 deletions.
101 changes: 51 additions & 50 deletions indication_paths.json
View file
Original file line number Diff line number Diff line change
Expand Up @@ -136374,7 +136374,7 @@
]
},
{
"comments": "The drug may also modulate other members of the Voltage-gated L-type calcium channel protein family (https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1275868/) or T-type calcium channel protein family (https://en.wikipedia.org/wiki/Azelnidipine).",
"comment": "The drug may also modulate other members of the Voltage-gated L-type calcium channel protein family (https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1275868/) or T-type calcium channel protein family (https://en.wikipedia.org/wiki/Azelnidipine).",
"directed": true,
"graph": {
"_id": "DB09230_MESH_D006973_1",
Expand Down Expand Up @@ -137113,7 +137113,7 @@
]
},
{
"comment": "At higher doses, bisoprolol antagonizes the B2 adrenergic receptors, but is mainly selective for B1 receptors.",
"comment": "At higher doses, bisoprolol antagonizes the B2 receptors, but is mainly selective for B1 receptors.",
"directed": true,
"graph": {
"_id": "DB00612_MESH_D006973_1",
Expand Down Expand Up @@ -137899,11 +137899,11 @@
]
},
{
"comment": "The drug needs to be converted to vidarabine phosphate first (monophosphate --> diphosphate --> triphosphate) to become active and exert its role as inhibitor (https://pubchem.ncbi.nlm.nih.gov/compound/21704#section=Mechanism-of-Action).",
"comment": "This disease is also known as Herpes simplex keratitis as per DrugCentral. The drug needs to be converted to Vidarabine Phosphate first (monophosphate --> diphosphate --> triphosphate) to become active and exert its role as inhibitor (https://pubchem.ncbi.nlm.nih.gov/compound/21704#section=Mechanism-of-Action).",
"directed": true,
"graph": {
"_id": "DB00194_MESH_D016849_1",
"disease": "Herpes simplex keratitis",
"disease": "Keratitis, Herpetic",
"disease_mesh": "MESH:D016849",
"drug": "vidarabine",
"drug_mesh": "MESH:D014740",
Expand Down Expand Up @@ -137996,7 +137996,7 @@
{
"id": "MESH:D016849",
"label": "Disease",
"name": "Herpes simplex keratitis"
"name": "Keratitis, Herpetic"
}
],
"reference": [
Expand All @@ -138006,10 +138006,11 @@
]
},
{
"comment": "This disease is denoted as Herpes simplex dendritic keratitis in the original file as per DrugCentral. The drug needs to be converted to Vidarabine Phosphate first (monophosphate --> diphosphate --> triphosphate) to become active and exert its role as inhibitor (https://pubchem.ncbi.nlm.nih.gov/compound/21704#section=Mechanism-of-Action).",
"directed": true,
"graph": {
"_id": "DB00194_MESH_D007635_1",
"disease": "Herpes simplex dendritic keratitis",
"disease": "Keratitis, Dendritic",
"disease_mesh": "MESH:D007635",
"drug": "vidarabine",
"drug_mesh": "MESH:D014740",
Expand Down Expand Up @@ -138102,7 +138103,7 @@
{
"id": "MESH:D007635",
"label": "Disease",
"name": "Herpes simplex dendritic keratitis"
"name": "Keratitis, Dendritic"
}
],
"reference": [
Expand All @@ -138112,7 +138113,7 @@
]
},
{
"comments": "This disease is denoted as Malignant neoplasm of liver in the original file as per DrugCentral.",
"comment": "This disease is denoted as Malignant neoplasm of liver in the original file as per DrugCentral.",
"directed": true,
"graph": {
"_id": "DB00322_MESH_D008113_1",
Expand All @@ -138124,7 +138125,7 @@
},
"links": [
{
"key": "produces",
"key": "has metabolite",
"source": "MESH:D005467",
"target": "CHEBI:46345"
},
Expand Down Expand Up @@ -145278,7 +145279,7 @@
]
},
{
"comments": "Drospirenone seems to have much lower affinity to androgen receptor than to the progesterone counterpart (https://en.wikipedia.org/wiki/Drospirenone#Pharmacology).",
"comment": "Drospirenone seems to have much lower affinity to androgen receptor than to the progesterone counterpart (https://en.wikipedia.org/wiki/Drospirenone#Pharmacology).",
"directed": true,
"graph": {
"_id": "DB01395_MESH_D000152_1",
Expand Down Expand Up @@ -145368,7 +145369,7 @@
]
},
{
"comments": "The use of progesterone, progestin and similar compounds may not be superior to placebo in reducing premenstrual symptoms judging from the results of the majority of controlled trials (https://pubmed.ncbi.nlm.nih.gov/7791258/). Also note that it is generally agreed that neither a deficiency nor excess in progesterone/progestin levels is etiologically relevant to the disorder (https://pubmed.ncbi.nlm.nih.gov/16650465/). It's largelly accepted that SSRIs as better treatment and should be the first attempt for treatment of premenstrual dysphoric disorder.",
"comment": "The use of progesterone, progestin and similar compounds may not be superior to placebo in reducing premenstrual symptoms judging from the results of the majority of controlled trials (https://pubmed.ncbi.nlm.nih.gov/7791258/). Also note that it is generally agreed that neither a deficiency nor excess in progesterone/progestin levels is etiologically relevant to the disorder (https://pubmed.ncbi.nlm.nih.gov/16650465/). It's largelly accepted that SSRIs as better treatment and should be the first attempt for treatment of premenstrual dysphoric disorder.",
"directed": true,
"graph": {
"_id": "DB01395_MESH_D065446_1",
Expand All @@ -145392,7 +145393,7 @@
{
"key": "positively correlated with",
"source": "UniProt:P08235",
"target": "MESH:D015222"
"target": "InterPro:IPR001696"
},
{
"key": "regulates",
Expand All @@ -145406,7 +145407,7 @@
},
{
"key": "regulates",
"source": "MESH:D015222",
"source": "InterPro:IPR001696",
"target": "GO:0070294"
},
{
Expand Down Expand Up @@ -145453,9 +145454,9 @@
"name": "Mineralocorticoid receptor"
},
{
"id": "MESH:D015222",
"id": "InterPro:IPR001696",
"label": "GeneFamily",
"name": "Sodium Channels"
"name": "Voltage gated sodium channel, alpha subunit"
},
{
"id": "GO:0005890",
Expand Down Expand Up @@ -145495,7 +145496,7 @@
]
},
{
"comments": "The disease is denoted Menopausal flushing in the original file. Note that a combination therapy of estradiol and drospirenone would be more effective at reducing the frequency of hot flushes and other menopausal symptoms, than a mono-therapy relying on progestin only. Also, since many progestogens have off-target effects including estrogenic effects, the improvement in hot flashes maybe due to the drug binding to estrogen receptors instead. Note the term Vasomotor System (https://en.wikipedia.org/wiki/Vasomotor_center) does not seem to be represented in other ontologies.",
"comment": "The disease is denoted Menopausal flushing in the original file. Note that a combination therapy of estradiol and drospirenone would be more effective at reducing the frequency of hot flushes and other menopausal symptoms, than a mono-therapy relying on progestin only. Also, since many progestogens have off-target effects including estrogenic effects, the improvement in hot flashes maybe due to the drug binding to estrogen receptors instead. Note the term Vasomotor System (https://en.wikipedia.org/wiki/Vasomotor_center) does not seem to be represented in other ontologies.",
"directed": true,
"graph": {
"_id": "DB01395_MESH_D019584_1",
Expand Down Expand Up @@ -145588,7 +145589,7 @@
]
},
{
"comments": "Note that the combination therapy of estradiol and drospirenone would be more effective at treating atrophic vaginitis, than a mono-therapy relying on progestin only. Also, since many progestogens have off-target effects including estrogenic effects, the improvement in hot flashes maybe due to the drug binding to estrogen receptors instead.",
"comment": "Note that the combination therapy of estradiol and drospirenone would be more effective at treating atrophic vaginitis, than a mono-therapy relying on progestin only. Also, since many progestogens have off-target effects including estrogenic effects, the improvement in hot flashes maybe due to the drug binding to estrogen receptors instead.",
"directed": true,
"graph": {
"_id": "DB01395_MESH_D059268_1",
Expand Down Expand Up @@ -146035,7 +146036,7 @@
]
},
{
"comments": "Etidronate is a weak inhibitor of proton transport in animal models (https://pubmed.ncbi.nlm.nih.gov/8889850/).",
"comment": "Etidronate is a weak inhibitor of proton transport in animal models (https://pubmed.ncbi.nlm.nih.gov/8889850/).",
"directed": true,
"graph": {
"_id": "DB01077_MESH_D010001_1",
Expand Down Expand Up @@ -146534,7 +146535,7 @@
]
},
{
"comments": "Note that this drug is used as a support to the treatment of chronic alcoholism by producing an acute sensitivity to ethanol (as part of an avoidance therapy for alcohol abuse). It's been suggested that disulfiram itself is unlikely responsible for the enzyme inactivation in vivo; several active metabolites of the drug, especially diethylthiomethylcarbamate, inhibits the enzyme in vitro (https://pubchem.ncbi.nlm.nih.gov/compound/3117#section=Mechanism-of-Action).",
"comment": "Note that this drug is used as a support to the treatment of chronic alcoholism by producing an acute sensitivity to ethanol (as part of an avoidance therapy for alcohol abuse). It's been suggested that disulfiram itself is unlikely responsible for the enzyme inactivation in vivo; several active metabolites of the drug, especially diethylthiomethylcarbamate, inhibits the enzyme in vitro (https://pubchem.ncbi.nlm.nih.gov/compound/3117#section=Mechanism-of-Action).",
"directed": true,
"graph": {
"_id": "DB00822_MESH_D000437_1",
Expand All @@ -146548,11 +146549,11 @@
{
"key": "negatively regulates",
"source": "MESH:D004221",
"target": "Pfam:PF00171"
"target": "UniProt:P05091"
},
{
"key": "positively regulates",
"source": "Pfam:PF00171",
"source": "UniProt:P05091",
"target": "GO:0006069"
},
{
Expand Down Expand Up @@ -146586,17 +146587,17 @@
"target": "HP:0002017"
},
{
"key": "correlated with",
"key": "negatively correlated with",
"source": "HP:0001033",
"target": "MESH:D000437"
},
{
"key": "correlated with",
"key": "negatively correlated with",
"source": "HP:0002098",
"target": "MESH:D000437"
},
{
"key": "correlated with",
"key": "negatively correlated with",
"source": "HP:0002017",
"target": "MESH:D000437"
}
Expand All @@ -146609,9 +146610,9 @@
"name": "disulfiram"
},
{
"id": "Pfam:PF00171",
"label": "GeneFamily",
"name": "Aldehyde dehydrogenase family"
"id": "UniProt:P05091",
"label": "Protein",
"name": "Aldehyde dehydrogenase, mitochondrial"
},
{
"id": "CHEBI:15343",
Expand Down Expand Up @@ -146996,7 +146997,7 @@
]
},
{
"comments": "MESH:D003865 is denoted as Depressive Disorder, Major in the MESH website. Note that the drug may slighlty inhibit the reuptake of serotonin too.",
"comment": "MESH:D003865 is denoted as Depressive Disorder, Major in the MESH website. Note that the drug may slighlty inhibit the reuptake of serotonin too.",
"directed": true,
"graph": {
"_id": "DB00234_MESH_D003865_1",
Expand Down Expand Up @@ -156562,7 +156563,7 @@
]
},
{
"comments": "MESH:D014987 is denoted as Xerostomia in MESH.",
"comment": "MESH:D014987 is denoted as Xerostomia in MESH.",
"directed": true,
"graph": {
"_id": "DB01085_MESH_D014987_1",
Expand Down Expand Up @@ -157184,7 +157185,7 @@
]
},
{
"comments": "Drug has been withdrawn in Europe due to increased risk of abuse or addiction, intoxication and events related to psychomotor impairment (https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1233/).",
"comment": "Drug has been withdrawn in Europe due to increased risk of abuse or addiction, intoxication and events related to psychomotor impairment (https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1233/).",
"directed": true,
"graph": {
"_id": "DB00395_MESH_D001416_1",
Expand Down Expand Up @@ -157269,7 +157270,7 @@
]
},
{
"comments": "Drug has been withdrawn in Europe due to increased risk of abuse or addiction, intoxication and events related to psychomotor impairment (https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1233/).",
"comment": "Drug has been withdrawn in Europe due to increased risk of abuse or addiction, intoxication and events related to psychomotor impairment (https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1233/).",
"directed": true,
"graph": {
"_id": "DB00395_MESH_D009128_1",
Expand Down Expand Up @@ -157324,7 +157325,7 @@
]
},
{
"comments": "Drug has been withdrawn in Europe due to increased risk of abuse or addiction, intoxication and events related to psychomotor impairment (https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1233/).",
"comment": "Drug has been withdrawn in Europe due to increased risk of abuse or addiction, intoxication and events related to psychomotor impairment (https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1233/).",
"directed": true,
"graph": {
"_id": "DB00004_MESH_D016410_1",
Expand Down Expand Up @@ -157962,7 +157963,7 @@
]
},
{
"comments": "The disease is known as Chagas Disease in MESH (MESH:D014355). The drug is metabolized by nitoreductases (https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213464s000lbl.pdf) rather than nitoreductases being the target of this drug (https://go.drugbank.com/drugs/DB11820#BE0010011).",
"comment": "The disease is known as Chagas Disease in MESH (MESH:D014355). The drug is metabolized by nitoreductases (https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213464s000lbl.pdf) rather than nitoreductases being the target of this drug (https://go.drugbank.com/drugs/DB11820#BE0010011).",
"directed": true,
"graph": {
"_id": "DB11820_MESH_D014355_1",
Expand All @@ -157976,11 +157977,11 @@
{
"key": "produces",
"source": "MESH:D009547",
"target": "CHEBI:26519"
"target": "CHEBI:26523"
},
{
"key": "disrupts",
"source": "CHEBI:26519",
"source": "CHEBI:26523",
"target": "CHEBI:16991"
},
{
Expand All @@ -158002,9 +158003,9 @@
"name": "nifurtimox"
},
{
"id": "CHEBI:26519",
"id": "CHEBI:26523",
"label": "ChemicalSubstance",
"name": "radical"
"name": "reactive oxygen species"
},
{
"id": "CHEBI:16991",
Expand All @@ -158028,7 +158029,7 @@
]
},
{
"comments": "Withdrawn from the market in many countries. Never been marketed in the US.",
"comment": "Withdrawn from the market in many countries. Never been marketed in the US.",
"directed": true,
"graph": {
"_id": "DB04830_MESH_D003924_1",
Expand Down Expand Up @@ -170408,7 +170409,7 @@
]
},
{
"comments": "Unlike other NSAIDs, it does not inhibit cyclooxygenase or lipooxygenase (https://en.wikipedia.org/wiki/Benzydamine#Pharmacology).",
"comment": "Unlike other NSAIDs, it does not inhibit cyclooxygenase or lipooxygenase (https://en.wikipedia.org/wiki/Benzydamine#Pharmacology).",
"directed": true,
"graph": {
"_id": "DB09084_MESH_D010146_1",
Expand Down Expand Up @@ -171089,7 +171090,7 @@
]
},
{
"comments": "Dilators could open up airways and help to reduce cough (https://www.mayoclinic.org/diseases-conditions/chronic-cough/diagnosis-treatment/drc-20351580).",
"comment": "Dilators could open up airways and help to reduce cough (https://www.mayoclinic.org/diseases-conditions/chronic-cough/diagnosis-treatment/drc-20351580).",
"directed": true,
"graph": {
"_id": "DB01240_MESH_D003371_1",
Expand Down Expand Up @@ -171602,7 +171603,7 @@
]
},
{
"comments": "Camphor is analgesic (https://www.genome.jp/dbget-bin/www_bget?cpd:C00808). The activation of members of the transient receptor ion channel protein family applications lead to desensitization, which in turn contributes to the analgesic effects of camphor after prolonged/repeated applications (https://pubmed.ncbi.nlm.nih.gov/33804078/).",
"comment": "Camphor is analgesic (https://www.genome.jp/dbget-bin/www_bget?cpd:C00808). The activation of members of the transient receptor ion channel protein family applications lead to desensitization, which in turn contributes to the analgesic effects of camphor after prolonged/repeated applications (https://pubmed.ncbi.nlm.nih.gov/33804078/).",
"directed": true,
"graph": {
"_id": "DB01744_MESH_D001416_1",
Expand All @@ -171614,9 +171615,9 @@
},
"links": [
{
"key": "increases activity of",
"key": "decreases activity of",
"source": "MESH:D002164",
"target": "InterPro:IPR013555"
"target": "UniProt:O75762"
},
{
"key": "negatively correlated with",
Expand All @@ -171625,7 +171626,7 @@
},
{
"key": "regulates",
"source": "InterPro:IPR013555",
"source": "UniProt:O75762",
"target": "GO:0050968"
},
{
Expand All @@ -171650,9 +171651,9 @@
"name": "camphor"
},
{
"id": "InterPro:IPR013555",
"label": "GeneFamily",
"name": "Transient receptor ion channel domain"
"id": "UniProt:O75762",
"label": "Protein",
"name": "Transient receptor potential cation channel subfamily A member 1"
},
{
"id": "GO:0050968",
Expand Down Expand Up @@ -171878,7 +171879,7 @@
]
},
{
"comments": "Cholestyramine is a bile acid sequestrant (https://www.ebi.ac.uk/ols/ontologies/ncit/terms?iri=http://purl.obolibrary.org/obo/NCIT_C98148) and its ultimate action is to lower serum concentration of lipids, namely cholesterol, phospholipids, triglycerides, and cholesterol esters.",
"comment": "Cholestyramine is a bile acid sequestrant (https://www.ebi.ac.uk/ols/ontologies/ncit/terms?iri=http://purl.obolibrary.org/obo/NCIT_C98148) and its ultimate action is to lower serum concentration of lipids, namely cholesterol, phospholipids, triglycerides, and cholesterol esters.",
"directed": true,
"graph": {
"_id": "DB01432_MESH_D006949_1",
Expand Down Expand Up @@ -171933,7 +171934,7 @@
]
},
{
"comments": "Cholestyramine is a bile acid sequestrant (https://www.ebi.ac.uk/ols/ontologies/ncit/terms?iri=http://purl.obolibrary.org/obo/NCIT_C98148) and its ultimate action is to lower plasma cholesterol concentrations.",
"comment": "Cholestyramine is a bile acid sequestrant (https://www.ebi.ac.uk/ols/ontologies/ncit/terms?iri=http://purl.obolibrary.org/obo/NCIT_C98148) and its ultimate action is to lower plasma cholesterol concentrations.",
"directed": true,
"graph": {
"_id": "DB01432_MESH_D006937_1",
Expand Down Expand Up @@ -171988,7 +171989,7 @@
]
},
{
"comments": "DrugBank and ChEMBL seem to disagree on the target of this drug (UniProt:P43088 in ChEMBL, UniProt:P34995 in DrugBank). Hence using a more generic term (IPR008365) to encompass both entries from those two databases.",
"comment": "DrugBank and ChEMBL seem to disagree on the target of this drug (UniProt:P43088 in ChEMBL, UniProt:P34995 in DrugBank). Hence using a more generic term (IPR008365) to encompass both entries from those two databases.",
"directed": true,
"graph": {
"_id": "DB00429_MESH_D006473_1",
Expand Down
Loading

0 comments on commit 2c6f658

Please sign in to comment.